ICON Public Limited Company ICLR PHARMA
Company Overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.38.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $8.25B (+0.8% YoY); net profit $229.34M.
- Trailing 12 Months Year-on-year growth — revenue +1.2%, earnings -63.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.1%, profit CAGR -23.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.15% |
| 1 Year: | 1.20% |
Compounded Profit Growth
| 5 Years: | -23.15% |
| 1 Year: | -63.30% |
Stock Price Performance
| 1 Year: | -10.18% |
| 6 Months: | +43.91% |
| 3 Months: | +4.01% |
| 1 Month: | -3.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.68 · Neutral
P/E of 247.41 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 247.4.
- Earnings shrank at -23.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ICLR ICON Public Limited Company PHARMA | 158.34 | 247.41 | $12.22B | 0.00% | 7.74% | 0.29% | 2.15% | -23.15% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.04B | 2.08B | 2.19B | 2.03B | 2.06B |
| Cost of Revenue | - | - | 1.46B | 1.54B | 1.69B | 1.56B | 1.58B |
| Gross Profit | - | - | 583.33M | 545.46M | 500.89M | 477.93M | 479.29M |
| Operating Expenses | - | - | 302.72M | 296.08M | 270.52M | 290.93M | 285.08M |
| Operating Income | - | - | 280.61M | 249.38M | 230.37M | 187.00M | 194.21M |
| EBITDA | - | - | 330.71M | -122.12M | 10.43M | 265.89M | 231.75M |
| Interest Expense | - | - | 50.15M | 50.24M | 40.11M | 48.00M | 48.79M |
| Pretax Income | - | - | 182.84M | -271.39M | -120.50M | 127.56M | 92.20M |
| Tax Provision | - | - | -20.67M | 12.79M | -10.36M | 22.81M | 19.61M |
| Net Income | - | - | 203.52M | -284.18M | -110.14M | 104.75M | 72.58M |
| Diluted EPS | - | - | 2.56 | -3.67 | 1.93 | 1.36 | 0.94 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 7.74B | 8.05B | 8.19B | 8.25B |
| Cost of Revenue | - | 5.53B | 5.71B | 5.82B | 6.08B |
| Gross Profit | - | 2.21B | 2.35B | 2.37B | 2.18B |
| Operating Expenses | - | 1.35B | 1.35B | 1.22B | 1.16B |
| Operating Income | - | 866.08M | 994.23M | 1.15B | 1.01B |
| EBITDA | - | 1.35B | 1.47B | 1.50B | 823.57M |
| Interest Expense | - | 209.19M | 311.02M | 206.20M | 188.11M |
| Pretax Income | - | 567.85M | 572.98M | 803.76M | 252.47M |
| Tax Provision | - | 59.41M | 18.39M | 64.63M | 23.13M |
| Net Income | - | 505.30M | 554.21M | 739.13M | 229.34M |
| Diluted EPS | - | 6.13 | 7.40 | 9.53 | 2.71 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 17.19B | 16.86B | 16.63B | 16.27B |
| Current Assets | - | 3.23B | 3.29B | 3.28B | 3.50B |
| Cash & Equivalents | - | 288.77M | 378.10M | 538.78M | 647.29M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.73B | 1.76B | 1.39B | 1.47B |
| Total Liabilities | - | 8.69B | 7.65B | 7.19B | 7.08B |
| Current Liabilities | - | 2.69B | 2.73B | 2.64B | 3.20B |
| Long Term Debt | - | 4.60B | 3.67B | 3.40B | 2.87B |
| Total Debt | - | 4.83B | 3.94B | 3.60B | 3.56B |
| Total Equity | - | 8.50B | 9.21B | 9.44B | 9.19B |
| Shares Outstanding | - | 81.72M | 82.50M | 80.76M | 76.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 563.32M | 1.16B | 1.29B | 1.04B |
| Investing Cash Flow | - | -145.87M | -226.65M | -266.79M | -187.53M |
| Financing Cash Flow | - | -864.17M | -844.04M | -837.18M | -771.26M |
| Capital Expenditure | - | -142.16M | -140.69M | -168.06M | -174.21M |
| Free Cash Flow | - | 421.15M | 1.02B | 1.12B | 861.99M |
| Net Change in Cash | - | -446.73M | 90.33M | 182.68M | 77.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 28.6% | 29.2% | 29.0% | 26.4% |
| Operating Margin % | - | 11.2% | 12.3% | 14.1% | 12.3% |
| Net Margin % | - | 6.5% | 6.9% | 9.0% | 2.8% |
| ROE % | - | 5.9% | 6.0% | 7.8% | 2.5% |
| ROCE % | - | 6.0% | 7.0% | 8.2% | 7.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Artisan Partners Limited Partnership | 11.31% | 8.64M | $1.42B |
| 2 | Wellington Management Group, LLP | 6.97% | 5.32M | $873.07M |
| 3 | FMR, LLC | 6.90% | 5.27M | $865.08M |
| 4 | Invesco Ltd. | 6.89% | 5.26M | $863.91M |
| 5 | Harris Associates L.P. | 5.85% | 4.47M | $733.27M |
| 6 | Brave Warrior Advisors, LLC | 4.13% | 3.15M | $517.49M |
| 7 | Greenhaven Associates, Inc. | 4.06% | 3.10M | $508.84M |
| 8 | Principal Financial Group, Inc. | 3.86% | 2.95M | $484.28M |
| 9 | Massachusetts Financial Services Co. | 2.76% | 2.11M | $345.48M |
| 10 | Ruane, Cunniff & Goldfarb L.P. | 2.68% | 2.05M | $336.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ICLR
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOd2w3ckxlaVpfNEpwOWFubDhoMExfS3g5ZEk0dENMXy00aHdER1V4NkhlanBrMXhNR0g3R0ZkcHZvUWNkVlhoekdlWTZWekpPUWRtRHJoT01XQXRQLU9TRUhVSEsyTXEwbmZRS05ITXpPa0hiZHN3d2ZtNmVBdmdNSURySlhJYUZuakNQZH…
ICON (ICLR) Stock May Be 27% Below Fair Value Despite ESG Progress - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNMXo5MFpybWhfb21SRzZrclJIaWVVMC1oS01RaXlZeE1lVVVlRVRwZGdzTEpFdDR6aEJYRmRfZEp4cXY4UUpGSnUwSEk5MmJHZ2IyaFpyRTFvV3pQTFFmUXVid0tLUXdvWUdCaFR0NUpLblZBTHoyRklmdTlFWl9rZUZaMlBCQjJUWk5IQ3…
ICLR - Icon Plc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1rUEg2Mnp1UWdLZ2NlX3dpQlBqc1hvTTRkRmhEM1FyTWFONlJsODhrdm9DbU1aYXJMRFJXd1pnY2dFbVNWelE?oc=5" target="_blank">ICLR - Icon Plc Stock Price and Quote</a> <font color="#6f6f6…
ICON Public Limited Company ($ICLR) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOclNybDY1T0h3ZlB4UmlSaS1nZVdEYllzcUVTekRVa3picTZnSjJQOEFsWUVYSy1UNmdIUXd1X3JXV0Q1ckw0cVVlSmE3bVNaZFpqQWcyNkNkajRPZDVuSUJVSjBYUlpWT1V1Q1NRbnhRcmpuSm9jZnZZTDdXV3JhZUVaY2ZObFpkbF9sTU…
ICON Plc (ICLR) Stock Analysis: Exploring Growth Potential With A 9.14% Upside - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOV1ZWX1NLclhUWkxMS18wbkx0dVljLVJkOGNJV0RBUUVtN0pKWXB5OE9LTm93QV9Qd1NJYWE4eW44UmR3QkJYU0x2SGdKcHJNVS1rMVgyMmtQNlMzRGNHNGVob3RWNU04RHpYbkpfdFFWZ3J1bFo0azVnVGhaTXBvbHprdXpUb2Z0bXBKMH…
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxONkhhclZMNVdTekpKXzVhb1lYT19HVWJjRUt0WGRoYXBhREdJODZKX2VmWjc4SWlSMzg3MzZJNDc3UDhwazZURjk2eWFWSTlONDJFQ3hCamI3dTQzNHNqTUpiQmVEN05ocEJvUk8tMVI3dzBpeEc0WjNNMkRWbkRQcEpIMXJ4UXk2Mnc?oc…
ICLR — Frequently Asked Questions
What is the current share price of ICON Public Limited Company (ICLR)?
As of 2026-09-19 21:16 PDT, ICON Public Limited Company (ICLR) trades at $158.34 on NasdaqGS. Its 52-week range is $80.08 to $202.92.
What is the market capitalisation of ICLR?
ICON Public Limited Company (ICLR) has a market capitalisation of $12.22B on NasdaqGS.
What is the P/E ratio of ICLR?
ICLR trades at a trailing price-to-earnings (P/E) ratio of 247.41. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.35.
What is the return on equity (ROE) of ICLR?
ICLR has a return on equity (ROE) of 0.29%. Its return on capital employed (ROCE) is 7.74%.
Is ICLR a good stock to buy?
This page provides a data-driven analysis of ICON Public Limited Company (ICLR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.